MODERNA, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 107.6 USD | +1.34% |
|
+5.76% | +7.84% |
| Apr. 24 | Sector Update: Health Care Stocks Slipping Late Afternoon | MT |
| Apr. 24 | Moderna to Collaborate With OpenAI to Launch New Generation of Medicines | MT |
Presenter SpeechStéphane Bancel (Executives)Well, good morning, everybody. Good afternoon, if ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Calendar
2024-05-02
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
106.2
USD
Average target price
134.3
USD
Spread / Average Target
+26.48%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +8.01% | 40.65B | |
| +1.93% | 42.59B | |
| +49.22% | 40.57B | |
| -11.96% | 26.77B | |
| +9.37% | 24.81B | |
| -24.33% | 18.17B | |
| +27.28% | 12.05B | |
| -3.22% | 11.7B | |
| +6.80% | 11.1B | |
| -17.20% | 9.85B |
- Stock Market
- Equities
- MRNA Stock
- News Moderna, Inc.
- Transcript : Moderna, Inc. - Special Call
